NEOSCAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEOSCAN is an injectable diagnostic agent developed by GE HealthCare, approved in 1978 as an NDA product. The specific mechanism of action and therapeutic indications are not publicly disclosed in available data, though the injectable route suggests use in imaging or diagnostic procedures. The product's long market tenure indicates established clinical utility in a specialized medical setting.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team contraction or transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Started Oct 2011
42 enrolled
Lung Cancer
Career Relevance
NEOSCAN currently shows zero linked job openings, reflecting its mature, stable status with limited growth trajectory. Working on this product offers expertise in diagnostic market dynamics and LOE management but may provide limited advancement opportunities compared to growth-stage portfolios.
Diagnostic Product Manager
Worked on NEOSCAN at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.